RecruitingNot ApplicableNCT05283044
Implementing Precision Medicine in cOmmunity HospiTALs
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Enrollment
10,000 participants
Start Date
Jun 29, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a biological treatment called biopsy liquid for people with metastatic cancer. The study is currently recruiting participants at 21 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALbiopsy liquid
Patient performs a blood test at treatment baseline
Locations(21)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05283044
Related Trials
Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.
NCT052451361 location
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT0526762618 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT0465706882 locations
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
NCT070436081 location
SLV-154 Treatment of Advanced Cancers
NCT0677121910 locations